The upcoming earnings report and the estimated EPS of $-0.04 are crucial factors that could impact the stock price of Protalix BioTherapeutics. However, the company's past performance shows a mixed trend of beating and missing EPS estimates, making it difficult to predict the short-term impact on the stock. The stock has been performing well over the past year, which could potentially influence investor sentiment positively.